Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Cancers|May 28, 2020
Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic AnalysisLaura Soumoy, Corentin Schepkens, Mohammad Krayem, et al.
Elife|February 22, 2022
The oxygen sensor prolyl hydroxylase domain 2 regulates the in vivo suppressive capacity of regulatory T cellsYousra Ajouaou, Abdulkader Azouz, Anaëlle Taquin, et al.
Molecular Cancer Research : MCR|March 20, 2021
Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-KitMalak Sabbah, Mohammad Krayem, Ahmad Najem, et al.
Frontiers in Medicine|May 22, 2023
The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanomaMalak Sabbah, Ahmad Najem, Christophe Vanderkerkhove, et al.
Cancers|August 4, 2019
The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in MelanomaMohammad Krayem, Malak Sabbah, Ahmad Najem, et al.
European Journal of Medicinal Chemistry|July 1, 2018
Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cellsAmel Djehal, Mohammad Krayem, Ahmad Najem, et al.
Frontiers in Oncology|December 6, 2021
Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational ValueAhmad Najem, Jasper Wouters, Mohammad Krayem, et al.
Cancers|December 23, 2023
Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. <i>Cancers</i> 2019, <i>11</i>, 1093Mohammad Krayem, Malak Sabbah, Ahmad Najem, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2016
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenibMohammad Krayem, Fabrice Journe, Murielle Wiedig, et al.
Cells|November 26, 2022
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug ResistancePashalina Kehagias, Nadège Kindt, Mohammad Krayem, et al.
Pageof 4